Summary
Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that develops, produces and markets research-based cortico steroids and steroid-hormone APIs. The laboratory’s cortico-steroids APIs includes betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate and clopredno, among others. It offers hormones APIs such as conjugated estrogens, desogestrel, drospirenone, estradiol and derivatives, esterified estrogen, estrone, ethinyl estradiol, ethisterone and ethynodiol diacetate. Symbiotec’s other products include abiraterone acetate, exemestane and rocuronium bromide. The laboratory operates its manufacturing unit in Pigdamber and Pathampur, India. Symbiotec is headquartered in Indore, Madhya Pradesh, India.
Symbiotec Pharmalab Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 8
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deal Details 9
Private Equity 9
Actis Completes Acquisition Of Interest In Symbiotec Pharmalab For US$48 Million 9
Symbiotec Pharmalab Raises US$9.93 Million In Private Equity Financing 11
Acquisition 12
Actis Capital May Sell 70% Stake in Symbiotec Pharmalab for up to USD280 Million 12
Symbiotec Pharmalab Ltd - Key Competitors 13
Key Employees 14
Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16
List of Tables
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Key Facts 1
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 1
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 8
Actis Completes Acquisition Of Interest In Symbiotec Pharmalab For US$48 Million 9
Symbiotec Pharmalab Raises US$9.93 Million In Private Equity Financing 11
Actis Capital May Sell 70% Stake in Symbiotec Pharmalab for up to USD280 Million 12
Symbiotec Pharmalab Ltd, Key Competitors 13
Symbiotec Pharmalab Ltd, Key Employees 14
Symbiotec Pharmalab Ltd, Other Locations 15
List of Figures
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Symbiotec Pharmalab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7